Novo Diabetes Drug & Novartis SMA Therapy: Latest Updates
- A summary of recent pharmaceutical developments, including positive Phase 2 trial results for Novo Nordisk's amycretin and expanded FDA approval for Novartis' Itvisma gene therapy.
- A next-generation treatment from Novo Nordisk, called amycretin, has demonstrated promising results in a phase 2 clinical trial for patients with diabetes.
- This news is notably critically important for Novo Nordisk, as the company faces increasing competition from Eli Lilly's products in the obesity and diabetes markets.Amycretin is being developed...
“`html
Novo Nordisk’s Amycretin Shows Promise & Novartis Gene Therapy expansion – Pharma News Roundup
Table of Contents
A summary of recent pharmaceutical developments, including positive Phase 2 trial results for Novo Nordisk’s amycretin and expanded FDA approval for Novartis’ Itvisma gene therapy.
Novo Nordisk’s Amycretin: Phase 2 Trial Results
A next-generation treatment from Novo Nordisk, called amycretin, has demonstrated promising results in a phase 2 clinical trial for patients with diabetes. The drug led to notable reductions in blood sugar levels and significant weight loss, according to a report by Bloomberg. Specifically, patients experienced an average weight loss of 14.5%.
This news is notably critically important for Novo Nordisk, as the company faces increasing competition from Eli Lilly’s products in the obesity and diabetes markets.Amycretin is being developed in both injectable and oral formulations, offering potential flexibility for patients. Novo plans to initiate a phase 3 study of amycretin for diabetes in the coming year.
FDA Expands Approval of Novartis’ Itvisma Gene Therapy
The U.S. Food and Drug Management (FDA) has broadened the approved use of Novartis’ gene therapy, Itvisma, to include older patients with spinal muscular atrophy (SMA). Reuters reports that Itvisma is now authorized for treating SMA patients aged 2 years and older who have a confirmed mutation in the survival motor neuron 1 (SMN1) gene.
Itvisma shares the same active ingredient as Zolgensma, Novartis’ existing SMA therapy, which is currently approved for patients under 2 years of age. Though, Itvisma carries a higher wholesale acquisition cost of $2.59 million, compared to $2.1 million for Zolgensma.
Understanding Spinal Muscular Atrophy (SMA)
Spinal Muscular Atrophy is a rare genetic disease affecting motor neurons, leading to muscle weakness and atrophy. The severity of SMA varies depending on the type, with Type 1 being the most severe and typically manifesting in infancy. Gene therapies like Itvisma and Zolgensma aim to deliver a functional copy of the SMN1 gene to address the underlying genetic defect.
| Gene Therapy | Approved Age Range | Wholesale Acquisition Cost |
|---|---|---|
| Zolgensma (Novartis) | < 2 years | $2.1 million |
| Itvisma (Novartis) | ≥ 2 years | $2.59 million |